IQVIA (NYSE:IQV) Upgraded at Barclays

IQVIA (NYSE:IQV) was upgraded by stock analysts at Barclays from an “equal weight” rating to an “overweight” rating in a research report issued to clients and investors on Friday, MarketBeat.com reports. The brokerage presently has a $210.00 target price on the medical research company’s stock. Barclays‘s price target points to a potential upside of 17.65% from the stock’s current price.

A number of other analysts have also weighed in on IQV. BMO Capital Markets set a $250.00 target price on shares of IQVIA in a research report on Friday, February 6th. Truist Financial cut their price objective on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Jefferies Financial Group reduced their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. JPMorgan Chase & Co. dropped their target price on IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. Finally, Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $231.13.

IQVIA Stock Performance

NYSE:IQV opened at $178.50 on Friday. IQVIA has a twelve month low of $134.65 and a twelve month high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. The stock’s 50-day simple moving average is $208.27 and its 200 day simple moving average is $207.49. The firm has a market capitalization of $30.29 billion, a PE ratio of 22.71, a price-to-earnings-growth ratio of 1.71 and a beta of 1.39.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, analysts anticipate that IQVIA will post 10.84 EPS for the current fiscal year.

Institutional Trading of IQVIA

Several institutional investors have recently added to or reduced their stakes in the stock. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA in the 4th quarter worth approximately $25,000. Physician Wealth Advisors Inc. increased its position in shares of IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after buying an additional 134 shares during the period. International Assets Investment Management LLC bought a new position in IQVIA during the fourth quarter worth $27,000. Gilpin Wealth Management LLC acquired a new position in IQVIA in the fourth quarter valued at $27,000. Finally, CrossGen Wealth LLC bought a new stake in IQVIA during the fourth quarter valued at $28,000. 89.62% of the stock is currently owned by institutional investors.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.